Adjuvant chemotherapy for high-risk operable breast cancer

Journal of Clinical Oncology

Volumn 25, Issue 13, 2007, Pages 1642-1644

  Buzdar, Aman U ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIESTROGEN; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TRASTUZUMAB;

ADJUVANT THERAPY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; EDITORIAL; FOLLOW UP; GENE EXPRESSION; HAND FOOT SYNDROME; HIGH RISK PATIENT; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; ONCOGENE C MYC; PERICARDIAL EFFUSION; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; RISK FACTORS;

EID: 34249069172     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.9796     Document Type: Editorial

References (32)

1. Moore HCF, Green SJ, Gralow J, et al: Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup Study 9623. J Clin Oncol 25:1677-1682, 2007
2. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
3. The Breast International Group (BIG) 1-98 Collaborative Group: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005
4. ATAC Trialists' Group: Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 356:60-62, 2006
5. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 1992
6. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
7. Gianni L, Baselga J, Eiermann W, et al: European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). J Clin Oncol 23:7S, 2005 (suppl; abstr 513)
8. Buzdar AJ: Topoisomerase II alpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer. J Clin Oncol 24:2409-2411, 2006
9. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
10. Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313, 2005
11. Burnell M, Levine MN, Chapman JA, et al: A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA. 21: Results of an interim analysis. Presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-16, 2006 (abstr 53)
12. Berry DA: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:2356-2367, 2006
13. Fisher B, Anderson S, DeCillis A, et al: Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 17:3374-3388, 1999
14. Antman KH, Rowlings PA, Vaughan WP, et al: High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 15:1870-1879, 1997
15. Rodenhuis S, Bontenbal M, Beex LVAM, et al: High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349:7-16, 2003
16. Roche H, Viens P, Biron P, et al: High-dose chemotherapy for breast cancer: The French PEGASE Experience. Cancer Control 10:42-47, 2006
17. Zander AR, Kroger N, Schmoor C, et al: High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. J Clin Oncol 22:2273-2283, 2004
18. Nitz UA, Mohrmann S, Fischer J, et al: Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: Results of a multicentre phase III trial. Lancet 366:1935-1944, 2005
19. Venturini M, Del Mastro L, Aitini E, et al: Dose-dense adjuvant chemotherapy in early breast cancer patients: Results from a randomized trial. J Natl Cancer Inst 97:1724-1733, 2005
20. Fountzilas G, Skarlos D, Dafni U, et al: Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: A randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 16:1762-1771, 2005
21. Bardia A, Loprinzi CL, Goetz MP: Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: A case series. J Clin Oncol 24:e18-e19, 2006 (e-correspondence)
22. Dang CT, D'Andrea GM, Moynahan ME, et al: Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clin Cancer Res 10:5754-5761, 2004
23. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
24. Green MC, Buzdar AU, Smith T, et al: Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983-5992, 2005
25. Seidman AD, Hudis CA, Raptis G, et al: Paclitaxel for breast cancer: The Memorial Sloan-Kettering Cancer Center experience. Oncology 11:20-28, 1997 (suppl 2)
26. Buzdar AU, Blumenschein GR, Smith TL, et al: Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast-cancer: A prospective randomized trial. Cancer 53:384-389, 1984
27. Buzdar AU, Hortobagyi GN, Kau SW, et al: Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. J Clin Oncol 10:1540-1546, 1992
28. Kay RG, Mason BH, Stephens EJ, et al: Levamisole in primary breast-cancer: A controlled-study in conjunction with L-phenylalanine mustard. Cancer 51:1992-1997, 1983
29. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
30. Kim C, Bryant J, Horne Z, et al: Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. Breast Cancer Res Treat 94:S6-S7, 2005 (suppl 1)
31. Slamon D, Eiermann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94:S5, 2005 (suppl 1)
32. Slamon D, Eiermann W, Robert N, et al: BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-16, 2006 (abstr 52)